Although GLP-1R agonists hold potential benefits for DM1 patients, evidence regarding their effectiveness and safety remains insufficient, and their direct impact on muscle function and disease progression is yet to be determined. This evidence concerns the gene GLP1R and myotonic dystrophy type 1.